ArticleAnnals of the rheumatic diseases2008
Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis.
Article in Annals of the rheumatic diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis in a Chinese population: a meta-analysis.Rheumatology international · 2012Pooled it
- Preclinical evaluation and pilot clinical study of [European journal of nuclear medicine and molecular imaging · 2022Article
- Isopsoralen ameliorates rheumatoid arthritis by targeting MIF.Arthritis research & therapy · 2021Article
- The challenge of using the rheumatoid arthritis diagnostic criteria in clinical practice.Internal and emergency medicine · 2015Article
- Low-field magnetic resonance imaging or combined ultrasonography and anti-cyclic citrullinated peptide antibody improve correct classification of individuals as established rheumatoid arthritis: results of a population-based, cross-sectional study.BMC musculoskeletal disorders · 2014Article
- Anomalies of intra-synovial citrullination: is there any interest in the diagnosis of early rheumatoid arthritis?Rheumatology international · 2013Article
- Synovial fluid and serum levels of IL-17, IL-23, and CCL-20 in rheumatoid arthritis and psoriatic arthritis: a Tunisian cross-sectional study.Rheumatology international · 2013Article
- Early diagnosis of rheumatoid arthritis: an introduction to the newly designed Iran Criteria for Rheumatoid Arthritis.Rheumatology international · 2013Article
- Anti-cyclic citrullinated peptide and rheumatoid factor in HIV positive patients.Rheumatology international · 2011Article
- Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.Current rheumatology reports · 2011Review
- RF vs. anti-CCP: competitor or companion?Rheumatology international · 2011Article
- Pattern-based diagnosis and screening of differentially expressed serum proteins for rheumatoid arthritis by proteomic fingerprinting.Rheumatology international · 2011Article
- Correlation of anti-cyclic citrullinated antibody with hand joint erosion score in rheumatoid arthritis patients.The Korean journal of internal medicine · 2010Article
- Review
- Significance of anti-CCP antibodies in modification of 1987 ACR classification criteria in diagnosis of rheumatoid arthritis.Clinical rheumatology · 2010Article
- The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis.Arthritis research & therapy · 2010Review
- Getting them even earlier: Identifying individuals before clinical presentation with rheumatoid arthritis.Arthritis and rheumatism · 2009Article
- Identification of undiagnosed inflammatory arthritis in a community health fair screen.Arthritis and rheumatism · 2009Article
- Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Arthritis and rheumatism · 2009Review
- Clinical approaches to early inflammatory arthritis.Nature reviews. Rheumatology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThe classification of rheumatoid arthritis (RA) is increasingly important as new therapies can halt the disease in its early stages. Antibodies to cyclic citrullinated peptides (anti-CCP) are widely used for RA diagnosis, but are not in the 1987 American College of Rheumatology (ACR) Criteria for RA Classification. We developed and tested the performance characteristics of new criteria for RA classification, incorporating anti-CCP.
methodsWe identified all subjects seen in our arthritis centre with rheumatoid factor (RF) and anti-CCP tested simultaneously between 1 January and 30 June 2004 and reviewed their medical records for the ACR criteria, rheumatologists' diagnoses, RF and anti-CCP. We revised the ACR criteria in two ways: (a) adding anti-CCP, and (b) replacing rheumatoid nodules and erosions with anti-CCP (CCP 6 criteria). We compared sensitivity and specificity of all criteria, in all subjects and in subjects with arthritis symptoms </=6 months.
resultsMedical records of 292 subjects were analysed: mean age was 54 years, 82% were women, and mean symptom duration was 4.1 years. 17% were RF positive and 14% were anti-CCP positive at initial testing. 78 (27%) had definite RA per treating rheumatologist at latest follow-up. The CCP 6 criteria increased sensitivity for RA classification for all subjects regardless of symptom duration: 74% vs 51% for ACR criteria with a loss in specificity (81% vs 91%). Sensitivity was greatly improved in subjects with symptoms < or =6 months: 25% vs 63% for ACR criteria with a decrease in specificity.
conclusionsThe CCP 6 criteria improved upon the sensitivity of the ACR criteria, most remarkably for subjects with symptoms < or =6 months and could be used for the classification of subjects for RA in clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.